Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The search for more effective and safer antiepileptic drugs (AEDs) remains a priority in neurological research. Brivaracetam (BRV), a newer generation AED, has garnered attention for its efficacy. A recent in vitro study has provided deeper insights into its cellular mechanisms, particularly its effects on glial cells – astrocytes and microglia – which are increasingly implicated in epilepsy. This research offers valuable information for those involved in the purchase of pharmaceutical chemicals and the development of neurological disorder therapeutics.
The study observed that brivaracetam, at therapeutic concentrations, influenced microglial activation states. In inflammatory co-culture models, BRV led to a reduction in resting microglia and an increase in activated microglia. This suggests a potential role for brivaracetam in modulating neuroinflammatory processes, a critical factor in refining epilepsy treatment. For researchers seeking advanced pharmaceutical intermediates, NINGBO INNO PHARMCHEM CO.,LTD. offers high-purity brivaracetam suitable for such investigations.
Furthermore, the research assessed the impact of brivaracetam on glial cell viability. While therapeutic doses did not induce significant toxicity under inflammatory conditions, a high concentration of BRV (20 μg/ml) was found to reduce cell viability in physiological environments. This finding is essential for those utilizing brivaracetam as a neuroscience research tool, highlighting the importance of dose-appropriate application and understanding potential side effects.
The study also investigated the expression of connexin 43 (Cx43) and gap junctional communication. Brivaracetam did not significantly alter Cx43 expression but showed a minor positive effect on gap junction coupling under physiological conditions at a low dose. These insights are valuable for ongoing in vitro drug efficacy testing and for developing more targeted epilepsy treatment strategies.
As a supplier of quality brivaracetam, NINGBO INNO PHARMCHEM CO.,LTD. plays a crucial role in enabling research that advances our understanding of neurological conditions. By providing reliable access to brivaracetam, they support the scientific community's efforts to refine therapeutic approaches and improve patient outcomes in epilepsy care.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
